Skip to main content
. 2018 Aug 7;13(8):e0201537. doi: 10.1371/journal.pone.0201537

Fig 1. Serum concentrations of FGF23 at baseline and at week 40 in patients that achieved a serum phosphate concentration of <4.5 mg/dL and >4.5 mg/dL).

Fig 1

(A) Change in iFGF23 concentration; (B) change in serum cFGF23 concentration. Bars represent median and interquartile range. Serum iFGF23 decreased from 581.0 pg/mL (491.2–886.0) to 238.5 pg/mL (116.7–443.5) [median percent change of 63.8% (-75.2–5.40) in patients that achieved the target of phosphate <4.5 mg/dL. In patients with serum phosphate >4.5 mg/dL, iFGF23 increased from 709.0 pg/mL (179.0–1247.5) to 1445.0 pg/mL (884.0–1500), [median percent change of 65.3% (9.1–368.1). cFGF23 did not decreased in those patients that achieved the target [median percent change -36.3 (-60.1–48.3). However, in patients with a final serum phosphate >4.5 mg/dl, it increased from 864.5 RU/mL (262.7–1299) to 3402.0 RU/ml (1899.0–8875), [median percent change of 206.9% (108.9–1056.3)]. * P <0.05 vs baseline. # P <0.05 versus same time different group. ## P<0.001versus same time, different group.